ENDOTHELIAL DYSFUNCTION IN ISCHEMIC HEART DISEASE
https://doi.org/10.20996/1819-6446-2008-4-4-23-27
Abstract
Aim. To assess the role of endothelial vasodilating, vasoconstrictive and adhesive dysfunction in the development of angina pectoris (AP) in patients with ischemic heart disease (IHD).
Material and methods. 83 patients with IHD were included in the study. 30 patients had AP of functional class (FC)-II, 27 patients - FC-III and 26 patients - FC-IV. The control group consisted of 25 healthy persons. Bicycle ergometry, daily ECG monitoring and echocardiography were used for verification of IHD. Endothelial vasodilating function was assessed by endothelium-dependent (EDVD) and endothelium-independent vasodilatation (EIDVD) of brachial artery. Vasoconstrictive function was assessed by the level of endothelin (ET-1). Endothelial adhesive function was evaluated by plasma concentration of intracellular adhesion molecules – JCAM-1, VCAM-1 and Е-selectin.
Results. Normal EDVD and EIDVD were observed in patients with AP of FC-II. The more severe FC of AP the more prominent endothelial vasodilating dysfunction was revealed as well as the higher levels of ET-1 and intracellular adhesion molecules. Patients with AP of FC-IV had hyperexpression of JCAM-1, VCAM-1, Е-selectin and ET-1 and low levels of EDVD and EIDVD.
Conclusion. Progression of IHD related with growing endothelial vasodilating, vasoconstrictive and adhesive dysfunction.
About the Authors
N. E. ZakirovaRussian Federation
R. G. Oganov
Russian Federation
A. N. Zakirova
Russian Federation
M. P. Plotnikova
Russian Federation
G. M. Salakhova
Russian Federation
References
1. Оганов Р.Г., Масленникова Г.Я. Профилактика сердечно-сосудистых заболеваний – реальный путь улучшения демографической ситуации в России. Кардиология 2007;(1):4-7.
2. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J 2006;27:1341-81.
3. Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997;100:2153-7.
4. Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004;109(23 Suppl 1):III27-32.
5. Vanhoutte P.M. Endothelial control of vasomotor function: from health to coronary disease. Circ J 2003;67:572-5.
6. Teerlink J.R. Endothelins: pathophysiology and treatment implication in chronic heart failure. Current Heart Failure Reports 2005; 2:191-7.
7. Oliveira G.H. Novel serologic markers of cardiovascular risk. Curr Atheroscler Rep 2005;7:148-54.
8. Landmesser U., Hornig B., Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109:27-33.
9. Ковалев И.А., Марцинкевич Г.И., Суслова Т.Е., Соколов А.А. Дисфункция эндотелия у лиц с отягощенной по атеросклерозу наследственностью. Кардиология 2004;(1):39-42.
10. Соболева Г.Н., Погорелова О.А., Кузнецова Т.В. и др. Влияние валсартана, флувастатина замедленного высвобождения и их комбинации на артериальное давление, показатели липидного об- мена и функцию эндотелия у больных гипертонической болезнью. Кардиология 2007;(11):9-13.
11. Rich S., McLaughlin V.V. Endothelial receptors blockers in cardiovascular disease. Circulation 2003;108:2184-90.
12. Ситникова М.Ю., Максимова Т.А., Хмельницкая К.А. и др. Неко- торые показатели состояния эндотелия у больных ишемической болезнью сердца, осложненной сердечной недостаточностью. Сборник научных трудов, посвященный 100-летию кафедры факультетской терапии имени академика Г.Ф. Ланга. СПб: СПбГМУ; 2000. С. 241-6.
13. Dupuis J., Tardif J.C., Cernacek P., Throux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation. 1999;99(25):3227-33.
14. Celermajer D.S., Sorensen K.E., Gooch V.M. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
15. Cooke J.P. Role of nitric oxide in progression and regression of atherosclerosis. West J Med 1996; 164:419-26.
16. Патарая С.А., Преображенский Д.В., Сидоренко Б.А., Масенко В.П. Биохимия и физиология семейства эндотелинов. Кардиология 2002;(6):78-85.
17. Price D.T., Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med. 1999;107:85-97.
18. Лутай М.И. Разрыв атеросклеротической бляшки и его клинические последствия. Можно ли предотвратить коронарную катастрофу? Укр кардіол журн 2002;(5):45-9.
19. Gearing A., Newman W. Circulation adhesion molecules in disease. Immunol Today 1993;14:506-16.
20. Marui N., Offermann M.K., Swerlick R. et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression age regulated through an antioxidant – sensive mechanism in human vascular endothelial cells. J Clin Invest 1993;92:1866-74.
21. Волков В.И., Серик С.А. Провоспалительные цитокины и растворимая молекула адгезии-1 при ИБС. Кардиология 2002;(9):12-6.
22. Hwang S.J., Ballantyne C.B., Sharrett A.R. et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96:4219-25.
23. Libby P., Ross R. Cytokines and growth regulatory molecules. In: Fuster V., Ross R., Topol E.J., eds. Atherosclerosis and coronary artery disease. Vol. I. Philadelphia: Lippincott-Raven, 1996. p.585-94.
24. Закирова Н.Э., Хафизов Н.Х., Карамова И.М., Закирова А.Н., Оганов Р.Г. Иммуновоспалительные реакции при ишемической болезни сердца. Рационал Фармакотер Кардиол 2007;(2):16-9.
Review
For citations:
Zakirova N.E., Oganov R.G., Zakirova A.N., Plotnikova M.P., Salakhova G.M. ENDOTHELIAL DYSFUNCTION IN ISCHEMIC HEART DISEASE. Rational Pharmacotherapy in Cardiology. 2008;4(4):23-27. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-4-23-27